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ABSTRACT
Planning for vaccines manufacturing capacity is both a complex task requiring many inputs and
an important function of manufacturers to ensure the supply of vaccines that prevent life-
threatening illnesses. This thesis explores the development of an operations based long range
capacity planning model to facilitate the annual strategic capacity planning review at Novartis
Vaccines. This model was developed in conjunction with process owners at Novartis Vaccines
and utilizes operations principles, non-linear optimization, and process data to efficiently
calculate the capacity of the vaccine manufacturing network. The resulting network capacity is
then compared to the long range demand for vaccine production to determine capacity deficits
and surpluses in the current manufacturing network as well as analyzing options for more
efficient capacity usage.
Although this model was developed specifically with respect to the Novartis Vaccines
manufacturing network, the capacity calculation and gap analysis tools for single and multi-
product facilities as well as batch allocation for in multi-product, multi-facility networks are also
applicable to other companies and industries that utilize batch processing. The model was
validated utilizing process information from a production line that was already operating near
capacity and showed a 95% agreement with the data from this line. Additionally, this operations
based planning model was able to achieve buy-in from both process owners and the global
strategy organization allowing it to be implemented in the planning cycle. Use of this tool
enables efficiency and transparency in capacity analysis as well as the tools to examine the
impact of a range of scenarios on the manufacturing network.
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1 Introduction
1.1 Problem Statement
Long range capacity planning allows vaccine manufacturers to identify shortfalls in their
available production capacity compared to the forecasted demand for the life saving vaccine
products they manufacture. The long range time frame allows manufacturers to plan and execute
capacity, regulatory, and third party manufacturing capacity adjustments as necessary based on
demand. It also enables manufacturers to look forward and plan for the introduction of new
products in the pipeline. The purpose of this thesis project is to develop a model that will allow
Novartis Vaccines & Diagnostics to more efficiently balance commercial demand and production
capacity in the two to five year timeframe.
1.2 Background and Motivation
Prior to this project, for 2-5 year (long range) global capacity planning, Novartis Vaccines
primarily used a manual method of identifying shortfalls by matching available capacity, as
identified by each facility, to the long range expected commercial demand. This manual method
is resource intensive and involves redefining manufacturing capabilities for each product every
year. The planning process usually involves limited interaction between planning for primary
production (bulk vaccine components) and planning secondary production (vaccine formulation
and filling) in allocating manufacturing capacity as well as in identifying methods to rectify
capacity shortfalls. Additionally, examining the manufacturing network on an individual facility
basis has the potential to lead to locally optimized manufacturing networks rather than a globally
optimized supply chain (Simchi-Levi, Kaminsky and Simchi-Levi 2008).
Novartis Vaccines also lacked a standard definition for what assumptions are included capacity
(or capability) calculations for vaccines manufacturing processes. This creates a variety of
"capacity" definitions throughout the organization and results in a variety of different
assumptions used in the capacities utilized for planning
1.3 Hypothesis
Operations principles and operational data can be used to calculate the capacity of both single
product and multi-product vaccines manufacturing equipment, and these capacity calculations can be
used to identify both capacity shortfalls and surpluses when compared to the commercial demand
forecasts for each year.
1.4 Methodology
The methodology utilized in this project involves two phases. The first is the development of a
standardized methodology to calculate the capacity of all of the process operations for Novartis
Vaccines and Diagnostics. Secondly, the resulting capacities are compared against the forecasted
commercial demand in the two to five year time horizon in a framework that allows analysis of
both a base case as well as the ability to conduct scenario analysis of the capacity utilization
effect of changes in various operational parameters.
1.4.1 Phase 1: Capacity Calculation
The initial capacity calculations are based on operations principles of identifying bottlenecks and
calculating process yields based on these bottlenecks. The calculations are also adjusted to
include a scheduling loss allowance for planned downtime and regulatory activities as well as
operating allowances for losses due to unplanned downtime and reject rate (based on operating
experience and/or historical data).
The capacity calculation methodology for each primary and filling line has been validated with
the process owner and tailored as necessary to fit the process using available data and guidance
from process experts. Process data such as cycle time, turnover time, and yields were collected
and/or validated by operations staff. For the current model, the formulation and packaging steps
are assumed not to be bottlenecks and are not included in the model.
1.4.2 Phase 2: Long Range Planning Model
The long range planning model connects the commercial demand forecast with the production
capacity. This model contains the linkages between final product demands, various locations and
production lines where each product can be filled, vaccine components in each product,
component production locations, and yield losses. Using the capacities calculated in Phase 1, this
model identifies the capacity gaps and surpluses for each product, line, or production facility.
Furthermore, this model allows planners to analyze the effects of changing operations parameters
or conditions on the network capacity and expected utilization.
1.5 Results
Through thesis research at Novartis Vaccines facilities worldwide, a model based on operational
principles has been developed to enable planners to balance supply and demand in the
manufacturing network. The capacity model methodology was able to achieve a 95% agreement
with the performance of the validation lines, which are considered to be running at capacity.
Additionally, this long range planning model received the necessary buy-in from key process
owners and is being to be used as part of the Novartis Vaccines planning process.
1.6 Thesis Overview
This thesis is organized into five chapters. The first chapter covers the introduction of the project
and background. Chapter two provides some background into the importance and evolution of
the vaccines industry and overview of Novartis Vaccines. This chapter also gives an introduction
to the vaccine manufacturing process, regulatory control, and manufacturing challenges that
impact model development. The third chapter details the development and formulation of both
the capacity methodology and long range planning model. The fourth chapter gives the results of
the project. Chapter fives details model recommendations and conclusions for Novartis
Vaccines, as well as applications to other companies and industries. The variables that are
utilized in this thesis and equations and their definitions are included as Appendix A. All figures
and data contained in this thesis have been sanitized to protect the confidentiality of Novartis
Vaccines data.
2 Vaccines Industry and Novartis Overview
The United States Department of Health and Human Services defines a vaccine as "a product of
weakened or killed microorganism (bacterium or virus) given for the prevention or treatment of
infectious diseases" (US HHS). The weakened or killed viruses or bacteria are called antigens,
and they prevent diseases because when the immune system recognizes the antigens it begins to
produce antibodies that are able to help the body provide resistance to the full form of the disease
when exposed at a later time (Hoyt 2007).
2.1 Vaccines Development
The first major effective vaccine was developed in 1796 by Edward Jenner to prevent smallpox.
Previous attempts at smallpox vaccinations had been attempted by injecting smallpox or inhaling
smallpox scabs in an attempt to only get a mild case, but many people still died from this
practice. Jenner observed that patients who developed non-life threatening cowpox from their
exposure with cows did not develop the much more life threatening smallpox. Accordingly
Jenner developed a vaccine that would give people a mild version of cowpox to protect them
from smallpox. The term "vaccine" actually comes from this discovery. "Vacca" is the Latin
word for cow and "vaccina" was the virus used in the smallpox vaccine. Louis Pasteur applied
the term vaccine to all forms of prophylactic immunization beginning in 1881. In 1979, the
World Health Organization declared smallpox to be completely eliminated (Kit 2007), (The Gale
Encyclopedia of Science 2004).
In 1885, Louis Pasteur developed the first vaccine developed in a laboratory for rabies. The
vaccine consisted of a weakened live virus from infected rabbits. As Pasteur continued his
development of the rabies vaccine, he discovered that the rabies virus produced a weakened (or
attenuated) response in dogs when it had first been serially passed through rabbits. This
development of the attenuated live virus was a significant step in developing a safer vaccine with
lesser side effects. Live attenuated viruses can cause a mild form of the disease in a small
number of people, but significant protection against the full strength antigen. Vaccines for polio,
measles, rubella, mumps, yellow fever, influenza, and chickenpox are a selection of vaccines that
are still given as live attenuated viruses today (Kit 2007), (The Gale Encyclopedia of Science
2004), (Hoyt 2007).
Pasteur continued his experiments with the rabies vaccine to also discover that the rabies virus
could be "inactivated" by the chemical formalin so that it still caused an immune response but
was not infectious. Eventually, this lead to the development of other "inactivated" or "killed"
vaccines as well including vaccines for polio, mumps, influenza, Japanese encephalitis, and
equine encephalitis (Kit 2007). Because the antigens are dead, inactivated vaccines do not carry
the risk of developing a mild form of the diesase, but immunity from these vaccines generally
declines over time and multiple doses are often required (Hoyt 2007).
Subsequently, other types of non-infectious vaccines have been developed including
polysaccaride vaccines which contain only the polysaccaride coat of the virus linked to a carrier
protein. Polysaccaride vaccines have been useful in combating Hemophilus influenza type b
(HIB). Recombinant and subunit vaccines which are comprized of only the immunogenic viral
proteins linked to adjuvants or formed into vesicles are also non-infectious vaccines. The lack of
non immunogenic components limits the risk of exposure to infectious virus and adverse side
effects. The hepatitis B vaccine has been developed using recombinant subunit vaccine
technology in recombinant yeast cells which contain the gene for the hepatitis B antigen (Kit
2007), (The Gale Encyclopedia of Science 2004).
As vaccine technology continues to advance a number of vaccine technologies are in
development including vaccines using synthetic peptides, biosynthetic peptides, recombinant
protiens, DNA, and genetic engineering. These technologies are being developed in an attempt to
find safe and effective vaccines against a variety of diseases that kill at least 8 million people year
including pneumoncoccal pneumonia, AIDS, malaria, acute respiratory infection and rotavirus.
Routine vaccination of children and adults has been highly effective in minimizing the morbidity
associated with these diseases. Table 1 shows the advances that have been made in limiting
morbidity in the United States for a selection of commonly vaccinated diseases.
Table 1: U.S. Morbidity Rate Selected Diseases
Disease Maximum U.S. Morbidity 1998 U.S. Morbidity
# of cases Maximum Year # of cases
Diphtheria 206,939 1921 1
Measles 894,134 1941 100
Mumps 152,209 1968 666
Pertussis 265,269 1934 7405
Polio 21,269 1952 1
Rubella 57,686 1969 364
Source: Kit 2007
However, despite the progress, world-wide approximately four million people die every year
from vaccine preventable diseases including:
" Measles: 1,100,000 deaths
* Hepatitis B: 800,000 deaths
e Haemophilus influenzae type B (HIB): 500,000 deaths
" Tetanus: 500,000 deaths
e Pertussis (whooping cough): 350,000 deaths
* Rubella: 300,000 deaths
e Yellow fever: 30,000 deaths
Of these, children under five years old account for 1.4 million or 14% of the global mobidity for
children under five (World Health Organization). These deaths occur partially because of the
enormous challenge of vaccinating a global population, many of whom lack adequate healthcare.
In the United States and many European countries, some parents have chosen not to vaccinate
their children for safety, political, or religious reasons. This practice however, leaves their
children exposed to the devestating consequences of contracting vaccine preventable diseases.
During the U.S. measles epedimic of 1989, 18,000 people were infected. Even though the
measles vaccine had been available in the United States since 1960, only 15% of those who
contracted the disease had received a measles vaccine. Additionally, lack of proper (and
recommended) vaccination for pertussis (whooping cough) for many children in the United States
has resulted in approximately 30,000 American children per year contracting the disease (Kit
2007), (Alexandra & Markel 2005).
2.2 Major Players
As of the end of 2010, the vaccines industry is comprised of five major players:
GlaxoSmithKline, Sanofi Aventis, Merck, Pfizer, and Novartis, and these five companies supply
80% of the global vaccines market. Over the past 10 years, the vaccines industry has seen market
share consolidation as the number of major players decreased from fourteen in 1988 to these five
players in 2010. The majority of the players that exited the industry during this period can be
attributed to the small margins for vaccine production, the cost of vaccine research and
development, national vaccine policies, and liability concerns (Prifti).
Table 2: Top Five Global Vaccine Manufacturers
GlaxoSmith
Kline
Sanofi
Pasteur Merck
Pfizer
(Wyeth)
Novartis
Vaccines
Estimated 2009 Vaccines $ 5960 $ 5015 $ 3631 $ 3007 $ 2424
Revenue (million USD)
Cholera x
Diphtheria x x x x
Haemophilus influenza type B
(HIB)
Hepatitis A x x x
Hepatitis B x x x
Herpes Zoster (Shingles) x
Human Papillomavirus
(HPV or Cervical Cancer)
Influenza
(Seasonal and Pandemic) _______
Japanese Encephalitis x x
Measles x x x
Meningitis ACWY x x x
Mumps x x x
Pertussis
(Whooping Cough) X X X
Pneumococcal infections x x x x
Poliomyelitis (Polio) x x x
Rabies x x
Rotavirus x x
Rubella (German Measles) x x x
Tick Bourne Encephalitis (TBE) x
Tetanus x x x x
Tuberculosis x x
Typhoid x x
Varicella x x x
Yellow Fever x
Sources: Merck, Sanofi Pasteur, GlaxoSmithKline, Pfizer Inc., Novartis, Center for Disease Control and Prevention
The next five vaccine manufacturers are much smaller in market share and focus either on a more
narrow market or have only a few commercial products. They are as follows:
China National Biotechnology Corporation (CNBC): CNBC is the state owned
biotechnology company in China which produces vaccines for thirteen diseases. CNBG
enjoys a 80% market share for vaccines in China (DCVMN), (BioPharmaLink Profile).
Baxter International: Baxter is a global diversified healthcare company that manufactures
vaccines for Tick Bourne Encephalitis, Meningitis C, and influenza (Baxter).
CSL Limited: The CSL Biotherapies division manufactures the seasonal influenza vaccine
and acts as a third party distributor for other vaccine manufacturers in Australia and New
Zealand (CSL).
Crucell: Crucell is focused on producing vaccines for influenza, hepatitis A, hepatitis B,
typhoid fever, and cholera (Crucell).
Solvay: Solvay Biologicals, a division of Solvay Pharmaceuticals manufactures the seasonal
influenza vaccine (Solvay 2010).
In 2002, Dr Robert Goldberg of the Center of Medical Progress at the Manhattan Institute
described the pharmaceutical industry's view on vaccines as "a brackish backwater of other
biotechnology and pharmaceutical enterprises" (Goldberg 2002), but more recently the vaccines
industry has been undergoing a consolidation with global diversified healthcare companies. In
2004, Sanofi-Aventis acquired its vaccines division, Sanofi Pasteur as part of Sanofi-
Synth61abo's acquisition of Aventis. Novartis AG's vaccines division, Novartis Vaccines and
Diagnostics was formed with the acquisition of Chiron Corporation in 2006 (Novartis 2006), and
Pfizer entered the vaccines market with the acquisition of Wyeth in 2009 (Pfizer 2009). At the
end of 2010, Johnson and Johnson was in the process of acquiring vaccine manufacturer Crucell
(Crucell 2010).
2.3 Regulatory Control
Like the rest of the pharmaceutical and biotechnology industry, the vaccines industry is highly
regulated by the Food and Drug Administration (FDA) in the United States, the European
Medicines Agency (EMA) in the European Union, and many other regulatory bodies from other
countries where the company's products are sold. The World Health Organization provides
regulatory recommendations which are used by many national organizations. The quantity of
regulatory bodies, variation in regulations from different countries, and intensity of scrutiny in
both development and manufacturing of vaccines requires significant investment and effort put
into compliance by vaccine developers and manufacturers (WHO 2011), (FDA 2010), (The
College of Physicians of Philadelphia).
Government regulation of vaccines began in 1902 in the United States government passed a law
that later became known as the "Biologics Control Act". This was the first government
regulation on the quality of drugs and it established an agency to oversee biologics manufacturing
facilities. Licensing for biologic products began in the U.S. in 1944 The Division of Biologic
Standards, which later became part of the FDA, was formed in 1954.
During vaccine development, once promising vaccine candidates are identified and proven
nontoxic in animals or cells, they must undergo a series of clinical trials in humans to prove their
safety and efficacy. The vaccine material developed for these clinical trials must be
manufactured in accordance Good Manufacturing Practices. Human clinical trial requirements
vary slightly for each regulatory body, which sometimes requires different clinical trials to be
conducted in different countries. However, they generally progress to approval in three phases:
Phase I: Safety, appropriate dosage range, and side effects are studied using a very small
group of people (generally less than 100 people).
Phase II: Effectiveness, or efficacy, of the vaccine is studied in a larger group of people
(generally hundreds of people) against a placebo. Safety, dosage, side effects, and
method of delivery are also studied in this phase.
Phase III: Efficacy of the vaccine is studied in a very large group of people (generally
several thousand people) against a placebo as well as against other vaccines for the
disease already on the market. Safety and side effects also continue to be studied and the
much larger study population gives an opportunity to recognize rare side effects from the
vaccine.
Following successful completion of the Phase III clinical trial, the vaccine manufacturer files
licensing documentation with the appropriate regulatory authorities in each country where the
vaccine is to be marketed. In addition to product data for safety, efficacy, purity, and potency;
inspection of the manufacturing facilities and regulatory review of the product labeling is
generally required before approval is granted for most agencies. Upon approval from the
regulatory bodies, the vaccine can be administered to the approved population (The College of
Physicians of Philadelphia), (U.S. National Institutes of Health 2007), (FDA 2010).
Regulatory agencies continue to monitor the safety and efficacy of vaccines following regulatory
approval through inspections of manufacturing facilities and optional phase IV clinical trials for
pharmacovigilance or continuous monitoring of large populations that have taken the vaccine
(FDA 2005). In the United States, the FDA and CDC have developed a reporting system called
the Vaccine Adverse Event Reporting System, where anyone can report serious events following
vaccination. These reports are then investigated by the FDA and CDC. The FDA and CDC have
also developed the Vaccine Safety Datalink where researchers perusing approved studies can
access data about populations that have been vaccinated (The College of Physicians of
Philadelphia).
In order to be compliant with regulatory standards, vaccine manufacturers are required to produce
vaccines in accordance with current Good Manufacturing Practices (cGMP or GMP). These
standards provide guidance to vaccine industry on the minimum requirements for quality
production systems. The FDA, EMA, and other regulatory authorities inspect vaccines
manufacturing facilities regularly to ensure compliance with these regulations. There are GMP
standards for facility organization, personnel, training, facilities, process controls, equipment,
process and equipment validation, cleaning and maintenance processes, laboratory controls,
standard operating procedures, deviations, material handling, sampling, testing, record keeping,
packaging, labeling, and warehousing (21 CFR 210), (21 CFR 211).
2.4 Vaccine Manufacturing Processes
The vaccine manufacturing process consists of two major processes: bulk manufacturing and
fill/finish manufacturing.
2.4.1 Bulk Manufacturing
Bulk manufacturing, also called primary manufacturing, is the biological process of making the
bulk antigens (or active drug substances), as well as vaccine components that facilitate immune
response in some vaccines called adjuvants.
Novartis Vaccines primarily uses either egg-based, fermentation, or cell culture-based biological
processes to manufacture vaccine antigens. Although the exact process and necessary equipment
varies for each vaccine, the basic process steps for egg-based antigen production are:
inoculation, incubation, harvest, inactivation, and purification/concentration. Similarly, for
fermentation the steps would be: fermentation, harvest, inactivation, and purification and for cell
culture the steps would be: seed preparation, cell expansion, cell culture, and harvest.
Although many bulk processes share some of the same steps, producing more than one vaccine
on the same set of equipment depends on multi-product production not only being technically
feasible, but also on the regulatory feasibility, and set up and change over validation between
vaccines. Regulatory validation of production is required not only for the general process but
also for each facility and line. Additionally, many bulk processes have substantially long cycle
times and changeover times required between the production of each vaccine. Multi-product
production would not only require downtime for cleaning, sterilization and other changeover
activities, but also a significant ramp up period before the first bulk material from the next
vaccine was completed. Consideration of these factors generally leads vaccine manufacturers to
utilize specialized or dedicated bulk production facilities and suites, where either a single antigen
is produced or each of the antigens for a multi-valent vaccine is produced in series on the same
equipment. Where multiple vaccines are produced using the same bulk equipment, they are
generally very similar and of the same production type (egg-based, bacterial fermentation, etc.)
For example, flu production capacity is often used to produce multiple vaccines. All three strains
of the northern hemisphere seasonal influenza vaccine are often produced in series on the same
production line. When seasonal influenza production is completed, the same line is often used to
produce the southern hemisphere egg-based influenza vaccine or an influenza vaccine for
pandemic stockpiling.
2.4.2 Fill/Finish Manufacturing
Fill/finish manufacturing, also known as secondary manufacturing, generally consists of three
steps: formulating the vaccine by combining the bulk components in the correct amounts, filling
the liquid vaccine into its final presentation form, and packaging. Packaging requires placing a
label on container(s) of the vaccine components and then placing them as well as an information
leaflet into a blister pack and/or box. For vaccines that need additional stability or shelf life,
there is often an additional lyophilization, or freeze drying, step after filling that turns the liquid
vaccine into a solid that has to be reconstituted just before administration.
There are a variety of presentation forms that vaccines can be filled into. The primary forms are
pre-filled syringes and vials, although ampoules and plastic dispensers are also used for some
products particularly in developing countries. Figure 1 depicts each of these presentation forms
as well as a representative Novartis Vaccines product that is presented in that form for some
markets. It is not uncommon for vaccines to be filled in different presentation forms for different
markets depending on factors such healthcare provider's preference, economic advantages in
each market, and regulatory constraints.
An additional layer of complexity for planning is that some vaccines require more than one
presentation form to complete a single dose. Novartis Vaccine's meningococcal ACWY vaccine,
Menveo, is an example of such a vaccine. The MenA component of the vaccine is a solid in a
lyophilized vial, and the MenCWY components are in liquid form in a prefilled syringe or vial.
Figure 2 shows an example of packaging for a single dose of this product, which contains a
lyophilized vial, a pre-filled syringe, and two needles. Figure 2 shows the outer packaging for the
product as well as the package leaflet that are both assembled as part of the packaging process.
Figure 1: Examples of Vaccines Presentation Forms
C c
e_ ai
Pre-filled Syringe
- V
-;-~ ~\
Dispenser
Multi-dose Vial
Ampoule
Source: Novartis Vaccines
Figure 2: Menveo Kit Presentation
Source: Novartis Vaccines
2.5 Challenges of Seasonal and Pandemic Flu Vaccine Production
2.5.1 About Influenza and Influenza Vaccines
Influenza, or flu, is a respiratory infection that affects 5-15 % of the American population each
year during the winter months. The elderly and young children are most at risk for
complications. On average 23,600 people die in the United States each year from flu related
complications (CDC 2005).
Although the prevalent strains of influenza virus change from year to year, there are three main
types of influenza virus that circulate in humans and some other animals: types A, B, and C.
Type A is categorized into sub-types based on the presence of surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA). The naming convention uses the abbreviations H
and N respectively each followed by number assigned to the type of glycoprotein present. For
example, the recent "swine flu" epidemic was caused by a strain of the influenza A virus subtype
H1N1 (CDC 2005).
2.5.2 Seasonal Flu Production
Most vaccine products are non-seasonal and have limited seasonal variability in a given year.
However, the seasonal influenza (flu) vaccination is a highly seasonal product and an important
part of the vaccines portfolio for many vaccines manufacturers. North America seasonal
influenza epidemics typically occur during the late winter and early spring (Solvay 2010), (CDC
2005).
The seasonal influenza vaccine changes each year based on the strains of the flu vaccine that are
expected to be circulating in that year. For northern hemisphere flu, the World Health
Organization selects the three strains of the flu virus to be used in the influenza vaccination for
the upcoming season. These strains are released to vaccine manufacturers in February of each
year. Generally two influenza A type and one influenza B type strains are selected (Emory
Healthcare). Flu vaccine manufacturers then have until early fall when seasonal flu vaccinations
begin to develop vaccines utilizing the recommended strains, undergo clinical trials for safety (in
some markets), manufacture the antigens for all three strains, formulate the three antigens into a
trivalent vaccine, fill into the final vial or pre-filled syringe presentation forms, package, and
deliver the vaccines to distribution points. Because most vaccine manufacturers begin production
"at risk" in January based on what they expect the strain selection to be, North American seasonal
influenza vaccine primary manufacturing is limited from January to early fall of each year when
there is no longer an economically viable market for additional product. Additionally, because
the three strains for the vaccine are generally produced in series on the same equipment, the
secondary manufacturing for the influenza vaccine operates in an even more limited season as it
cannot begin until production lots of the third influenza strain begin to be released.
The seasonality of the influenza vaccine creates particular challenges in capacity and capability
planning. Planners must consider the viability of either only operating the facilities part of the
year, methods of producing other products in the off season to level-load the facility year round,
or operating at a high level of utilization during the flu production season and a much lower level
of utilization with other products during the off season.
2.5.3 Pandemic Flu Production
An influenza pandemic is generally caused by the emergence of a strain of the Influenza A virus
that is significantly different than other circulating strains (CDC 2005). In 1918, there was an
influenza pandemic that resulted in 40 million deaths worldwide (Solvay 2010). Pandemic
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influenza vaccines are generally produced in the same method as the seasonal influenza vaccine,
except that the antigen is produced for only one strain in the pandemic vaccine. When the
pandemic influenza vaccine is required it is generally because of a pressing public health need
and must be produced quickly and in large volumes to meet this need. In response to the avian
and swine pandemic flu scares of the past few years, many countries have taken steps to reserve
pandemic influenza manufacturing capacity and/or stockpile pandemic influenza vaccines. In
turn, pandemic planning has affected how vaccine manufacturers plan influenza capacity based
on incentives from these governments.
2.6 Novartis Company Background
2.6.1 Novartis Overview
Novartis AG is Swiss based company that seeks to provide healthcare solutions that address the
evolving needs of patients and societies worldwide. Novartis had revenue of $44 billion in 2009
and a global reach in their four major divisions. The divisions: Pharmaceuticals, Sandoz
(generics), Consumer Health, and Vaccines and Diagnostics represent a diverse portfolio of
healthcare solutions for Novartis's customers (Novartis).
2.6.2 Novartis V&D Overview
Novartis' Vaccines and Diagnostics division (NVD) is the smallest but fastest growing of all the
Novartis divisions. NVD posted revenues of $2.4 billion in 2009 with a growth rate of 13.9%
over the previous year. Over 800 million vaccine doses are shipped annually to 85 countries
resulting in a vaccine from Novartis providing potentially life-saving immunity to disease every
25 seconds (Novartis Vaccines).
2.6.2.1 Major Products
Novartis Vaccines produces vaccines for over 20 viral and bacterial diseases. It is the fifth
largest producer of vaccines in the world and the second largest supplier of influenza
vaccinations. Additionally, Novartis Vaccines produces Fluvirin, which is the second largest
selling seasonal influenza vaccine in the United States. Novartis Vaccines produces vaccines in
three product families: Flu, Meningitis, and Pediatric and Specialty vaccines. Table 3 gives a
representative list and description of Novartis Vaccines products.
Table 3: Selected Novartis V&D Products
Product Type Name Indication Description
Flu Agrippal (Agriflu) Seasonal influenza (egg based)
Fluvirin Seasonal influenza (egg based)
Fluad Seasonal influenza (egg based) - adjuvanted
Optaflu Seasonal influenza (cell culture based)
Aflunov Pandemic adjuvanted avian flu (egg based)
Celtura Pandemic influenza (cell culture based)
Focetria Pandemic influenza (egg based)
Meningitis Menjugate Meningococcal C
Menveo Meningococcal ACWY
Pediatric, Tetanol Tetanus
Specialty and Td-Pur Tetanus, diphtheria
Travel Vaxem Hib Haemophilus influenza type B (HIB)
Quattvaxem Diphtheria, tetanus, pertussis, and HIB
Quinvaxem Diphtheria, tetanus, pertussis, HIB, and hepatitis B
Polioral Oral polio (OPV)
Rabipur (RabAvert) Rabies
Encepur Tickbourne Encephalitis
Ixiaro Japanese Encephalitis
Source: Novartis Vaccines
2.6.2.2 Sites
The global Novartis Vaccines manufacturing network currently spans six sites in five countries.
Each site acts as a center of excellence for production of a particular type of vaccine, vaccine
im k i
component, or part of the vaccine manufacturing process. The global manufacturing network
consists of facilities in:
" Liverpool, England - Egg-based flu vaccine production
e Marburg, Germany - Travel and pediatric bacterial vaccine production (Tetanus,
Diphtheria, Pertussis, TBE, Rabies), Lyophilization
e Siena, Italy - Egg based flu vaccine production, Polio
* Rosia, Italy - Glycoconjugate bulk vaccine production, fill/finish and packaging
" Holly Springs, North Carolina USA - Flu Cell Culture bulk vaccine production, fill/finish
and packaging
e Ankleshwar, India - Rabies vaccine production, fill/finish and packaging
Contract manufacturers also form a key component of the vaccines manufacturing network.
These third parties provide an economic method of fulfilling peak demand periods or non-core
components of the manufacturing process. Contract manufacturers are also able to consolidate
demand for a particular type of technology that may be uneconomic at the volumes of individual
producers, but the volumes from several producers allow them to achieve economies of scale
unavailable to individual producers. Contract manufacturers primarily fulfill processes that are
not intellectual property intensive such as fill/finish and packaging.
2.6.2.3 Novartis Vaccines Development
Novartis formed its Vaccines and Diagnostic division in 2006 with the $5.4 billion acquisition of
Chiron. Chiron faced serious supply constraints and sterility problems. These resulted in the
shutdown of one of its production facilities by British regulators in 2005, which caused major
shortages of the influenza vaccine. Novartis led the turnaround effort with aggressive management
reorganization and growing the technical abilities of the organization. This turnaround enabled
Novartis Vaccines to be a leading provider of the 2009-2010 HINI pandemic influenza vaccination
and the first provider to achieve both European Union and United States regulatory approval for their
pandemic vaccine (Staton 2010), (Bigelow 2010).
Looking forward, Novartis has a strong pipeline of vaccines in development as illustrated in Figure 3.
The vaccines in development include a seasonal influenza vaccine produced in cell culture, approval
of the meningitis ACWY vaccine for additional age groups, a four-valent meningitis B vaccine,
group B streptococcus, H pylori, and HIV (Novartis Vaccines). Development of these vaccines and
others like them will continue to further Novartis Vaccine's mission of disease prevention.
Figure 3: Novartis Vaccine Pipeline 2010
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3 Model Development
The Long Range Planning Model is a capacity analysis model that uses operations data and
principles as well as non-linear optimization to calculate the capacity of each of the Novartis
Vaccines manufacturing processes. This model is designed to facilitate decisions about the
Novartis Vaccines manufacturing network design and product allocation. The model uses this
capacity information as well as Novartis Vaccine's demand forecast to efficiently identify gaps
between the demand and Novartis' capacity limited ability to supply. Positive gaps (more
capacity than demand) either indicate potential for greater production of current products or
potential locations to be considered for pipeline products. Negative gaps (more demand than
capacity), indicate that strategic decisions will be needed on how to best fill these gaps.
3.1 Model Timeframe
3.1.1 Timeframe Selection
The timeframe that was selected for the Long Range Planning Model is two to five years. This is
the time period the best balances the need for accuracy in the product mix and forecasted demand
with the need to act in advance of the demand or product launch to make capital investment or
regulatory changes. Figure 4 details the factors in selecting a planning model time frame.
The two to five year planning period is the timeframe in which significant capital (Cohen and
Roussel), staffing, or regulatory changes can be made to Novartis' internal capacity, but also a
timeframe in which contract manufacturing capacity can be secured if necessary and the
timeframe in which planning for phase III and commercial launch products takes place.
Additionally, planning for this time period is controlled by strategic decision making and this
time period corresponds to the time period covered by the annual Commercial Long Range Plan.
Figure 4: Factors in Planning Model Timeframe
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3.1.2 Timeline Implications on a Long Range Planning Model
Selecting a two to five year timeframe has specific implications on the assumptions used in the
Long Range Planning Model. As a result, the validity of the outputs is limited to this timeframe.
3.1.2.1 Demand Risk Pooling and Lead Time
The demand forecast on which the Long Range Planning Model is based is an annualized forecast
for each product. The Long Range Planning Model seeks to ensure that demand can be met on an
annualized basis for strategic planning purposes rather than on a detailed weekly or monthly
production schedule basis that would take into account order timing variability. However, in
practice, there is variation in how much of each vaccine is in demand each month, and planning
for maximum capacity utilization does not give the flexibility to handle these variations and
maintain the same service level (Simchi-Levi, Kaminsky and Simchi-Levi 2008).
As seasonal flu vaccines are a key part of Novartis' business and northern hemisphere flu must be
produced in a limited time frame, both primary and secondary flu capacity has been considered
by looking at "total" capacity, considering a 52 week year, and "seasonal" capacity which
considers a shorter northern hemisphere flu vaccine production season.
Although short term supply chain constraints are generally not considered relevant to this model
due to its forward looking nature, the annualized demand in the demand forecast is given based
on the year in which the vaccine needs to be available to the customer. The vaccine must go
through production, formulation, filling, and packaging. Each of these consumes production
time, but there are also various forms of testing and required hold times at certain points in the
process before the product can be released. As a result, the bulk vaccine manufacturing and
filling need to happen substantially before the demand occurs. To account for this lead time in
the model, the primary and secondary demand is backwards adjusted based on the lead time for
each product. This process assumes a steady demand over the course of the year (except for
influenza products), so that the primary production demand for a given year is approximately the
year that it actually needs to be produced.
3.1.2.2 Staffing
Often facilities that do not have sufficient demand to operate at equipment capacity operate at
staffing levels that are optimized for the current or expected near future demand. In these staffing
constrained cases, staffing levels and shift schedules have a significant impact on the capability
of the facility to produce product in the near term. Current staffing and shift scheduling may
continue to have a significant impact in the short term (zero to two years) as it takes a substantial
amount of time to increase staffing levels because newly hired operators must often participate in
a lengthy training and certification process. Therefore, for short term capability planning models
(zero to two years) it is logical to include these factors. However, over the longer term (two to
five years), staffing and shift structures can be changed to accommodate larger (or smaller)
demands. Therefore, the capacity of the process equipment should govern long term strategic
planning rather than current staffing levels or shift structures.
3.1.2.3 Inventory
Although margins of vaccine manufacturing are low relative to pharmaceuticals, vaccine
manufacturers often face a competitive bid structure to provide government agencies with
vaccines. The resulting demand can be highly variable as it depends on the outcome of the
bidding process. Missing or delayed product delivery to customers due to production problems or
lack of capacity can be devastating to company reputation and future business. In some cases,
customers actually order vaccines from several companies and cancel orders from the companies
with the longest lead times. Because of the high cost of losing a sale, both from the disease
prevention perspective and from an economic perspective, the vaccine industry generally
operates at very high inventory levels to reduce the possibility of shorting the market. However
these products often must be managed in a cold chain and therefore have a high cost of storage.
They are also products that have a defined shelf life, which can easily lead to costly inventory
write downs if not carefully managed (Cohen and Roussel 2005).
Analysis of these inventory levels is beyond the scope of this model, but the Long Range
Planning Model assumes that all processes are stable processes resulting in a constant average
level of inventory, such that the inventory level at the end of the year is the same as at the
beginning of the year (Anupindi, Chopra and Deshmukh). Therefore, for each year only the
demand level for that year needs to be produced. Neither utilizing safety stock nor stockpiling is
considered for the capacity gap analysis, although these factors may be very useful in mitigating
capacity shortages as they are identified in the model.
3.2 Capacity Model Overview
The capacity that the long range capacity model calculates is called the process capacity or
practical operational capacity. This capacity is the annualized production potential, based on the
maximum sustainable production rate of the process (Anupindi, Chopra and Deshmukh).
3.2.1 General Capacity Calculation Methodology
The long range capacity calculation methodology is an operations and optimization based
approach to calculating vaccine manufacturing capacity. Both operations principles and non-
linear mixed integer optimization programming is used to find the maximum theoretical capacity
for each process as well as a practical operational capacity to be used for capacity planning.
The model calculations begin by considering the maximum theoretical capacity. This is the
manufacturing capacity as limited by the process equipment. Under the maximum theoretical
capacity assumption, the equipment operates twenty four hours a day, seven days a week, 365
days per year. The theoretical capacity is calculated by examining each of the processing steps
and determining which step would produce the smallest amount of final product equivalents over
the same period of time. This limiting step is defined as the bottleneck step, which sets the
capacity for the entire process. The maximum theoretical capacity model explicitly excludes
losses due to manufacturing defects, batch losses due to nonproductive biological conditions, and
other losses including: maintenance, regulatory activities, line stoppages, equipment changeover,
cleaning and sanitization (Anupindi, Chopra and Deshmukh).
Once the maximum theoretical capacity case has been considered, the methodology
acknowledges that it is unrealistic to operate a production facility in this manner, and therefore
unproductive to utilize the maximum theoretical capacity for strategic planning. Both planned
and systematic unplanned losses are part of the operating system and including them in the
capacity calculation both improves accuracy of the capacity used in planning and assists decision
makers in identifying high impact losses that can be targeted for future process improvement
efforts. This process is illustrated in Figure 5.
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Some of the capacity losses are planned or required, such as planned maintenance downtime,
media fills (for sterility testing), changeover and sterilization time between each batch and
1 Capacities and losses are illustrative only
product produced on the same process, start-up time after shutdowns until product is produced
again, and scheduling losses due to regulatory production limitations. Some losses considered are
the result of manufacturing variability such as average reject rate, batch losses, and over fill, line
rate loss, and average allowance for unplanned downtime including corrective maintenance and
line stoppages. Once all of these losses have been subtracted from the maximum theoretical
capacity, the resulting capacity is the practical operating capacity as shown in Figure 5.
The practical operating capacity is the capacity that planners can use to determine how much to
expect a certain production facility to produce in a given year. The practical operating capacity is
the capacity that among other factors considers regulatory restrictions, average batch yield,
operating line speed, and makes an allowance based on historical data for unplanned downtime.
The throughput of the process will be less than the practical operational capacity due to lack of or
variation in demand, scheduling losses, and available workforce. As a result the following
inequalities exist:
Theoretical Maximum Capacity Practical Operational Capacity >Throughput
(Anupindi, Chopra and Deshmukh)
This methodology provides a robust approach to capacity calculation that can be applied to most
of Novartis Vaccines processing units as well as many other batch processing units across both
the vaccines and pharmaceutical industries and other industries. The limitation of this basic
methodology is that it requires that all products produced on the same equipment have the same
production characteristics and units of measure. Units of measure in this case can be defined
quite broadly. The most useful unit of measure is the same unit of measure of the demand
forecast (often doses), but other units of measure can be equally useful and can be converted
between doses of the demand forecast and production quantities. Units such as grams of active
drug substance or other appropriate units like LF units for tetanus and diphtheria are useful in
cases where many final products contain the same drug substance in different quantities. For
multi-product facilities which produce products that do not share similar production
characteristics, or where the common units approach is not sufficiently useful, a more complex
capacity calculation methodology is required.
3.2.2 Multi-Product Facility Capacity Calculation Methodology
Facilities or processes that produce multiple products often have substantially different process
characteristics like bottlenecks, cycle times, yields, or even process steps for each of the products.
These processes require additional steps beyond the general capacity calculation methodology
and are dependent on the product mix (Anupindi, Chopra and Deshmukh).
The one unit of measure that all processes with the same production characteristics have in
common is the use of time and occupation of production vessels. This commonality can be
exploited to allow the effective examination of multi-product facility capacities considering the
products that will be required to be processed in each facility. In addition to process parameters,
the capacity of these multi product facilities is also dependant on the regulatory approach to
producing multiple products in the same facility. Two approaches will be considered in this
section: product isolation by step and product isolation by product.
The multi-product capacity calculation methodology begins by carrying out the general capacity
calculation methodology on each of the products that is produced in a facility separately. For
example, if three products are produced in facility A, then the capacity of facility A would be
calculated based only on producing product 1, then only product 2, and only product 3. The
exception to the general capacity methodology in this case is that the facility should consider the
product changeover and start up for all the products in the process even though the capacity is
only in terms of a single product. This will give the capacity of the process in terms of
equivalents of each of the products produced on the line.
To further consider the impact of multiple products, it is necessary to understand the regulatory
environment and constraints on process controls that processing multiple products places on the
system. To prevent cross contamination that could take place from factors such as inadequate air
handling controls or mishandling of drug material used for different products, there are often
isolation procedures for upstream processes that prevent more than one product from being
produced in the same area at the same time. Although there are many ways to isolate products
within the system, this paper considers the two extremes: process isolation and step isolation.
Process isolation is when the entire upstream production process is limited to producing one
product at a time. Step isolation occurs when there are sufficient structural and/or process
controls to sufficiently isolate each step so that multiple products can be processed in the same
process but in different steps. Figure 6 illustrates how each of these constraints would affect
product production scheduling and process capacity.
An important variation of the Step Isolation model occurs when there are sufficient stockpiles of
intermediate inventory between process steps to allow the timing of each step in the production
process to be decoupled from the previous and following steps. This model involves significant
tradeoffs between process flexibility, utilization, and inventory holding costs. It also requires that
that intermediates are sufficiently stable to allow for inventory holding. Analysis of these
tradeoff factors is outside the scope of this paper. However, the capacity analysis will be
considered in both the Step Isolation and Step Isolation with intermediate inventory cases.
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Figure 6: Multi Product Production Methods
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For each of the scenarios, it is assumed that the entire demand of each product is produced in one
campaign in each year as this minimizes the amount of set up time required for each product and
thus gives a best case examination of capacity utilization. However, there are trade-offs between
the number of campaigns of each product and inventory holding costs due to scheduling and
demand variability and distribution over the course of the year. As long term demand scenarios
are annualized, examination of these factors is more suited to a short term planning analysis than
to this model.
In all three of the models the capacity estimation methodology considered the mode of operation,
demand for each year, and single product capacity analysis to determine how much of the process
and/or step capacity is consumed by the demand for each product. Once this has been determined
for each product, the sum of the utilizations either indicates a surplus of capacity or deficit. The
surplus or deficit gap can be translated into equivalent doses of any product produced in the
facility by considering the single product analysis.
3.2.2.1 Process Isolation
When the system lacks sufficient controls (process, HVAC, etc) to sufficiently isolate the
individual steps so that more than one product can be produced at the same time (in different
steps), production of the entire product must be completed before the production process can be
changed over for the new product and production started on it. Figure 6 illustrates a graphical
representation of a production schedule with the process isolation limitation.
In this case, there are additional losses that must be considered due to the fact that the bottleneck
step must not only wait at the beginning of the process to receive material, it must also stand idle
at the end of the process until the final batch is finished with its last step. The methodology for
considering process isolation in a multi-product facility involves a loss due to the changeover
process from the previous product, a productive loss due to process startup, and production
limited by the bottleneck step. The loss due to start up compensates for the idle time of the
bottleneck step while it is waiting for the output of previous steps and the idle time following the
completion of the final batch. The loss due to start up for process is equivalent to the minimum
time that it takes to complete one batch minus the cycle time of the bottleneck step. Figure 7
illustrates how the process isolation production schedule would look as compared to the
methodology the model uses.
Conceptually, the model considers the product produced on the same line in series. However, in
the model developed for the Long Range Planning Model all of the losses are considered first
when examining the capacity in equivalent units of a single product and then that product's
utilization of the rest of the capacity can be assessed as a percentage of remaining capacity for
each year based on demand. This process is repeated for all products produced in this process. If
the sum of all of the percentages of remaining capacity is greater than 100%, there is a production
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deficit. If the sum of percentages is less than 100%, there is a production surplus. Both deficits
and surpluses can be expressed in terms of any of the products on that process. In the process
isolation methodology, if all of the products have the same bottleneck the result is the same as the
step isolation method.
Figure 7: Process Isolation Methodology
Production Schedule Conceptual Model Approach Actual Model Approach
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3.2.2.2 Step Isolation
Step isolation for multi-product facilities occurs when the production process contains sufficient
controls so that production of multiple products can exist in the same production process at the
same time, but are limited to different steps of the process. For the initial consideration of this
case, no stockpiles of intermediate inventory stores will be held from previous or for subsequent
campaigns of each product, therefore, all of the available material for the product in process must
be completed before processing the next product on each step. It is also assumed that each step
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will be run for the minimum time possible, which may create some temporary intermediate
inventory if the previous process has a substantially longer cycle time per batch.
Because of the potential variation in cycle times for each step and product as well as variation in
location of bottleneck steps for each product, the order that products are processed may
substantially change the capability of the multi-product equipment. Figure 8 illustrates that as the
process bottlenecks shift for each product, that scheduling downtime is created for all of the
steps. In this case, scheduling optimization can be used to minimize downtime and maximize the
amount of vaccine material that can be obtained out of the process.
Figure 8: Step Isolation Scheduling Effects
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Although incorporating scheduling optimization was outside the scope of this project, the
capacity model does consider a special case of step isolation in multi-product facilities. This
special case occurs when all of the products produced on a particular process have the same
limiting bottleneck step. This is not an unlikely scenario, because in the vaccines industry many
upstream processes are limited to producing in the same equipment vaccine components that are
very similar and often simply different strains of the same disease.
When all the products have the same bottleneck step, the process is very similar to the process
isolation methodology, but the model only needs to consider one product start up loss after
annual maintenance, and then an additional product start up for every planned downtime when
there will be no product in the system. Figure 9 illustrates both the production schedule for this
special case of step isolation as well as the model methodology.
Figure 9: Step Isolation Methodology
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3.2.2.3 Step Isolation with Inventory
Processes that stockpile sufficient stores of intermediate work-in-progress inventory for each of
the products produced so that each step operates completely independent of each other and does
not need to wait for the previous step for input material, can be considered and modeled using the
Step Isolation with Inventory methodology. Because of the wealth of inventory, no start-up
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losses are incurred because the final step can begin production immediately without waiting for
material from the previous steps.
Additionally, each step is considered individually for all of the products produced using that step.
After product changeover losses are considered for each step, each product's utilization of the
rest of the capacity of that step can be assessed for each year based on demand. This process is
repeated for all products and steps in the process. The sum of utilization of remaining capacity
for each step reveals the step with the highest utilization. This indicates the limiting step for that
combination of products in each year. Because the mix of products varies from year to year
putting different amounts of pressure on the bottleneck step for each product the limiting step for
the mix of products may change from year to year. If the sum of all of the percentages of
remaining capacity is greater than 100% for the limiting step, there is a production deficit. If the
sum of percentages is less than 100% for the limiting step, there is a production surplus. Both
deficits and surpluses can be expressed in terms of any of the products produced on that step.
3.2.3 Multi-Product, Multi-Facility Decisions
In some cases, a single facility can produce multiple products, but a single product also has the
ability to be produced in multiple facilities. It is often the case that each facility may have certain
characteristics that will affect both its capacity and the network capacity based on the selection of
products that are allocated to that process. This is especially true in secondary (fill finish)
manufacturing in the vaccines industry. For example, a filling line that has no product
changeover loss above the regular batch changeover loss, but has a slower line speed may be the
best choice to run many low volume products. On the other hand, a line with a higher line speed,
but a very long changeover time may be more appropriate to a few high volume products.
Regulatory restrictions also play a role. Products can only be run on lines that they are validated
to be run on, and then they can only run for a validated length of time before the equipment
operations must be stopped and the line sterilized. This validated run time limits the size of a
batch for that particular product to the amount that can reliably be filled in that time window.
Because of this, batch sizes vary not only from product to product on the same line, but also vary
for the same product on different lines. The product batch size on a particular line affects the
process capacity by impacting the amount of losses due to turnover between batches. Given the
same product on two identical lines, but one with a small validated batch size and the other with a
very large validated batch size, the large batch size will produce many more doses in the span of
a year because of less time loss to changeover. Therefore, the allocation of products to different
lines is important in determining capacity.
The optimal product allocation for a given year can be determined by using a non-linear
optimization program in Excel Solver to determine which product allocation combination both
meets demand for the year and minimizes downtime losses due to batch and product changeover,
therefore, increasing total capacity potential. The details of this model are explored in the Model
Formulation section of this paper.
3.3 Inputs and Outputs Overview
3.3.1 Model Inputs
Capacity calculation requires input data that is currently housed in a variety of sources around the
organization principally: operations process owners, process improvement, planning, and supply
chain. The model update design seeks to standardize what information is required from each
source and process, and where possible obtain the information from a consistent documentation
location. Table 4 describes the information required and its source.
Table 4: Model Inputs and Sources
Information Source Owner
Demand Commercial Forecasting
Operational Assumptions / Data Site Operations Process Owners
Process cycle times, Process success rates Process Improvement Organization validated
with Process Owners
Lead times Supply Chain
Secondary Presentation Split Current: Supply Chain
Anticipated changes: Planning
Gross to Net Conversion Rate Supply Chain or Process Owners
3.3.1.1 Demand
The commercial long range demand forecast is the source of all of the demand numbers for the
Long Range Planning Model. This annually updated forecast provides two scenarios, which form
the basis for analyzing the sufficiency of the presently available capacity.
3.3.1.2 Operational Assumptions / Data
A wide variety of data or operating assumptions are used in the calculation of each process
capacity. Where possible, data has been used instead of assumptions in the model. The data or
assumptions included in the capacity calculation and the variables assigned to them include:
Variable Name Description
HD Maximum hours per day 24 hours
Dw Operating days per week 7 days
Wy Maximum weeks per 52 weeksyear
W Weeks of Seasonal Weeks of production for seasonal influenza production on
Sp Production process "p"
WM, Weeks of Maintenance Weeks of annual scheduled maintenance on process "p"
W Weeks of Ramp Up after Weeks of time required after process start up to start outShutdown putting product again on process "p"
WFp Weeks of Media Fill Weeks of non-productive processing due to regulatory
sterility testing on process "p"
Percentage of available time not impacted by unplanned
FUP Uptime Planning factor down time on process 'p)
Downtime Planning Percentage of available time impacted by unplannedFDtp factordown time such as line stoppages and corrective
factor maintenance on process "'p"9
Rsp Line Rate (Secondary) Production rate in units/min on process "p"
Bp Batch size Batch size in million doses (or million dose equivalents)for product "i" on process "p"
Fyip Batch yield Percentage yield of the initial batch size for product "i"
on process "p"
Percentage of initial batches that successfully grow
Fsip Batch success rate product within specification for product "i" on process
"p"
HBip Batch Changeover time Hours required to clean, sterilize, and set up for the nextbatch between batches for product "i" on process "p"
HOP Product Changeover time Hours required to clean, sterilize, and set up for the next
product after product "i" on process "p"
Hz Cycle Time Hours that one batch of product "i" is required to occupyHzjip Cyle Timethe process vessel(s) for step "6j" in process "4p"5
HT1J Takt Times Hours of process time after one batch starts until the nextbatch begins for product "i" on step "j" in process "p"
Due to the standardization present in the model, most of the processes use the same set of data
and assumptions to calculate capacity. However, due to special constraints or process differences
in some processes there are additional data needs.
3.3.1.3 Process Cycle and Takt Times
While all of the input information is important, using the process cycle times to calculate the takt
times is the most critical piece of information in determining capacity.
Cycle time (Hzijp) is the amount of time that a process step is occupied with activities related to a
particular batch. This includes processing time (HTijp) and a set of activities collectively called
batch changeover time (HBijp) which includes cleaning, sterilization, and set up for the next batch
(Equation 1).
V ip, Hzijp = HTijp + HBijp
Takt time (HTijp) indicates how frequently a new batch can be started. The easiest way to
calculate takt time is to determine the cycle time and divide by the number of batches that could
be on going at the same time (Bsijp) as given in equation 2.
H
V ijp, HTijp = ZYP
Bsup Equation 2
For example, if the cycle time for fermentation of Product A is 7 days for one fermentation, but
there are 3 fermentation vessels so the takt time is: (7*24)/3 = 56 hours. When determining
batch yield for each step (doses per lot), the batch or lot size must be defined the same way as it
was for calculating the cycle time for that step.
3.3.1.4 Lead Times
The demand forecast is an annual two to five year forecast and is given in terms of the year that
the vaccine needs to be ready to be delivered to the customer. However, because of the amount
of time required to produce, formulate, fill, and package the vaccines, as well as the amount of
delay caused by release testing at various stages of the process, production of the vaccine must
start substantially before the customer actually demands it.
The lead times allow the model to adjust the commercial demand forecast back to the year where
it would actually need to be produced and filled (assuming uniform demand over a year). The
two lead times of importance for this model are:
e Primary lead time (PLT): minimum time in months required from end of bulk production
to final product release
Equation 1
* Secondary lead time (SLT): minimum time in months required from filling to final product
release
In the model, the adjusted demands are referred to as Primary Demand and Secondary Demand
Equation 3 gives the demand adjustment equation for primary demand as an example assuming
that lead times are less than 12 months.
PDiy = Diy *(12-PLr )/12+ Dity+l) *( PLT /12) Equation 3
3.3.1.5 Secondary Presentation Split
Novartis Vaccines has several products that it provides in multiple secondary presentations such
as pre-filled syringe, vial, lyophilized vial, or ampoule. For the products with multiple
presentations, the proportion of the demand that will be filled in each form is a key factor in
determining the utilization of secondary capacity. The initial product splits are determined by the
current product mix and modified by any planned changes in presentation format.
3.3.1.6 Gross to Net Conversion Rate
During primary production, the number of doses (or yield) that can be produced based on the
bulk output of the primary production batch is called the gross yield. However, this yield does
not consider losses due to secondary processes or overfill and the combination of the two often
adds up to upwards of 30% loss. Net yield is the number of doses that can be obtained after these
losses are considered. The Gross to Net Conversion Rate refers to this percentage of secondary
loss and overfill that enables the accurate estimation of the number of doses that could actually be
delivered to a customer. The Gross to Net conversion rate is used at the end of every primary
capacity calculation to adjust the capacity to reflect the number of net doses.
3.3.2 Model Outputs
The output of the Long Range Planning Model displays process capacities, process demands,
utilizations, and the capacity gap for the two to five year planning period. This data is provided
in both numerical and graphical format to assist decision makers with planning. Figures 10 and
11 give an example of the Primary Model output for three example processes.
Figure 10: Primary Summary Quantitative Example2
Primr Capacity vs Demnd 201 2012 213 21M4 -2015
Proces A Capacity (units) 1870 1870 1870 1870 1870
Demand (units) 1864 1872 1695 1926 2370
Proces B Capacity (units) 1100 1100 1100 2000 2000
Demand (units) 1056 859 603 1078 1647
Proces C Capacity (units) 700 700 700 700 700
Demand (units) 681 806 591 211 196
Primary Utilization
Proces A 99.7% 100.1% 90.60% 126.7%
Proces B 96.0% 78.1% 54.9% 53.9% 82.4%
Proces C 97.3% 115.2% 84.4% 30.1% 28.0%
Primary Capacity Gaps (mds)
201 212 2013 304 2011
Proces A units 0.7 -0-2 21-5 -6.9 -61.5
Process B units 0.5 24.7 56.2 113.4 43.4
Process C units 2.3 -13.1 13.5 60.2 62.0
Figure 11: Primary Capacity Graphical Example3
Process A Process B Process C
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Product A Product B *0 Product C Product A i Product B Product C Product A Product B
Product D Product E Product F Product D Product E Product F Product C - Capacity
ProductG - Capacity - Capacity
2 Data are illustrative only and do not reflect Novartis Vaccines parameters
3 Figures are illustrative only
3.4 General Capacity Model Formulation
The primary goal of the capacity model is to calculate the practical operational capacity for each
process by considering the maximum production potential and the operational losses incurred.
Effective Available Weeks (WApy) is the number of weeks that the process is available to produce
product. It is calculated for each year, as shown in equation 4, by considering the Maximum
weeks per year (Wy) and considering the weeks of losses that come from planned maintenance
(WMpy), media fills (WFpy), ramp up after shutdown (WRpy), planned project downtime (Wcpy),
and an uptime planning factor (Fup). The calculation of the uptime planning factor is given as
one minus the percentage of available time impacted by unplanned downtime (FDp) such as line
stoppages and corrective maintenance (Equation 5).
Vy,p, WApy = (Wy - (WMPY + WFpy + WRpy + Wcpy)) * Fup Equation 4
Fup = 1 - Fpp Equation 5
The next step in calculating the practical operational capacity is to examine the production
process. For each step in the process the takt time of that step, as given in Equation 1, indicates
how often a new batch can be started on that step in a sustainable manner. From a long range
planning perspective, this takt time data is calculated based on equipment capacity and
processing time and specifically eliminating workforce constraints. The effective number of
batches that can be produced per week (Bwijp) on each step is given by dividing available hours
per week by the takt time for each step (Equation 6). For the long range planning model the base
assumption for hours per week is 24 hours per day and seven days of operations per week.
V i,j,p, Bwijp HD D
H7-ir Equation 6
If the 24 hours a day, seven days a week operations model is not the short term operational
model, it is expected that facilities could be ramped up to this level if necessary in the zero to two
year time frame. There are some cases where a lower assumption would be appropriate, such as
in cases where law or union contracts forbid operating on this schedule.
The number of effective batches per week is then multiplied by the effective number of weeks
per year from Equation 4 to give the practical operational production step capacity in batches
(BNijp )for each product on each step of the process (Equation 7). The practical
Vp,i,j, BNijp = WApy * Bwijp Equation 7
operational step capacity is much easier to compare to demand when examined in demand
equivalent units. Generally for vaccines the demand equivalent unit is in million doses. The
conversion to practical operational step capacity in doses (Cijp) (Equation 8) is achieved by
multiplying by the average number of expected doses per batch (BAijp). The average number
Vp,i,j, Cijp = BNijp * BAijp Equation 8
of expected does per batch can be calculated directly from operations data for the process.
However, from a loss analysis calculation perspective, if the relevant data is available it is useful
to consider the losses assumed when average number of expected does per batch is used.
Average number of expected doses per batch (BAijp) is calculated by considering the theoretical
doses per batch (Brijp) and the yield losses due to both process yield loss (Lyijp) which is the
percentage of the theoretical yield of active drug substance in each batch that is unable to be
recovered at the end of the process and batch loss (LBip) which is the percentage of process
batches that fail to grow (Equation 9). Because each step of the process may define the concept
of "batch" differently it is important that batch size or yields are consistent for each process step
with the definition of "batch" that was used for determining the cycle time for each step.
Vp,i,j, BAijp = BTijp * Lyij, * LBip Equation 9
Once the practical operational step capacity is determined for all the steps in the process, the
bottleneck step and therefore the process practical operational capacity can be determined. The
step capacity of the bottleneck (CBpi) is the minimum step capacity of all of the process steps in
demand equivalent units (Equation 10). The practical operational process capacity (Cpi) is limited
by the step capacity of the bottleneck.
Vp,i, CBpi = Min(Cijp) = Cpi Equation 10
3.5 Capacity Model Formulation Variations for Complex Cases
3.5.1 Multi-product Facilities
The model formulation for multi-product facilities uses the general capacity model as its base, but
utilizes the capacity analysis based on each product produced on the process to consider the
utilization based on the demand mix for a given year.
3.5.1.1 Process Isolation
For multi-product facilities that practice process isolation, the model development begins with
calculating the capacity based on the general methodology assuming that each product is the only
one produced on that line. Secondly the capacity methodology is modified to account for
additional losses due to producing multiple products, and then examine the fraction of available
capacity that must be allocated to products within the demand.
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The required changes to the base capacity model are primarily due to the fact that sharing
equipment with multiple products, the system incurs additional losses due to multiple start up
times and product changeovers. The available production week equation (Equation 4), is
adjusted by subtracting weeks of product changeover (WDpy) as defined in Equation 12 and
multiplying the weeks of ramp up after shutdown (W1 py) by the number of products produced in
that process (Npy) the resulting equation is given in Equation 11.
Vy,p, WApy = (Wy - (WMpy+WFpy+WRpy*Npy+Wcpy+WDpy)) * Fup Equation 11
H cp * NY
V yIp, WDpy S HD * DW Equation 12
Making these adjustments to the general capacity model results in the calculation of the practical
available capacity based on production of only one product, as if that product was produced on
the same production schedule as the many products produced in the facility. In order to consider
the effect of multiple products produced in the facility, the demand for each of the products must
be considered. For a given year and process, the percentage of practical available capacity
required to meet the demand is calculated for each product. The percentage sum of the all of the
fractional capacities indicates the portion of the practical available capacity and also the portion
of the available production weeks that are required to meet demand for the year. If the
percentages sum to less than 100%, there is a capacity surplus. A sum of fractional capacity
percentages greater than 100% indicates a capacity shortfall. The percentage of shortfall or
surplus can be analyzed as a percentage or converted into units of any of the products produced
on that process by multiplying by the practical available capacity for that product.
3.5.1.2 Step Isolation
In both the Step Isolation with Inventory models and the special case of the Step Isolation model
where all the products have the same bottleneck step on the process, the same formulation as the
Process Isolation formulation is used except that the Available Production Weeks equation
(Equation 11) is modified to fit the assumptions of each case. Specifically, the treatment of the
ramp up after shut down (WRpy) is different in each case. In the Process Isolation case, the ramp
up after shutdown was multiplied by the number of products. For the special case of the Step
Isolation model, only one ramp-up is required after the annual maintenance (Equation 13), and in
the Step Isolation with inventory case the intermediate inventory makes it unnecessary to
consider ramp-up time (Equation 14).
Vy,p, WApy = (Wy - (WMpy+WFpy+WRpy+Wcpy+WDpy)) * Fup Equation 13
Vy,p, WApy = (Wy - (WMpy+WFpy+WRpy+WCpy+WDpy)) * Fup Equation 14
Utilizing the appropriately calculated weeks of available production, the practical available
capacities of each process can be calculated using the general capacity methodology. The multi-
product analysis is subsequently carried out utilizing a similar percentage fractional capacity
method as the Process Isolation method. However, in the step isolation case the sum of
percentage utilizations for each process step must be considered individually. The step with the
highest total utilization indicates the bottleneck and therefore the process capacity.
In utilizing the step isolation with inventory process, different products may have different
bottlenecks on the same process. This methodology calculates the overall bottleneck for the
entire year based on the demands for products produced on each process. As the proportions of
each product demand change it is possible that the process bottleneck changes from year to year.
3.5.2 Multi-product, Multi-facility Capacities and Decisions
In situations where products can be produced in multiple facilities that also produce multiple
products; the allocation of products to facilities is important in optimizing the utilization of
capacity. A non-linear optimization program in Excel Solver is used to allocate batches of
product demand to each of the production lines to both utilize production capacity efficiently and
supply the demand (Anupindi, Chopra and Deshmukh). The capacity models that use the multi-
product facility formulation are utilized as part of the optimization model. The capacity models
provide input to the optimization and the outputs of the optimization model are utilized in the
capacity model. The objective function of this model is to minimize the total amount of required
down time on internal capacity due to batch changeovers (HBpy ) and product changeovers (Hepy)
and minimize the number of batches allocated to external capacity (BNiEy). To accomplish this,
the number of external batches is multiplied by a scaling factor (F,) in hours per batch, which is
slightly greater than the largest batch changeover time plus the largest product changeover time.
This scaling factor incentivizes the model to prioritize product allocation to internal capacity
rather than external capacity.
Objective Function: V y, Minimize (2 H Bpy + HcPY + F * BNiEy) (Equation 15)
P
Decision variables and constraints of the optimization model are detailed as follows:
Decision Variables: BNipy= batches of product "i" produced on process "p" in year "y"
BNiEy= batches of product "i" produced on external process "E" in
year "y"
Constraints: V yji, Di, = Sily
V y, Tupy fApy
V y, BNipy -0(
Where:
V i,y BNipy * Bsipy Sipy
Vi, y I (Sip, )= S ,
P
V p,y, TApy = WApy * Dw * HD
V p,y, Tupy = H1 py + HBpy + Hcpy
S(Si,, )
Vy, p, HTpy -
Vy, p, HBpy = (BNPy *H Bip
For each year product and year, supply must
equal demand (Equation 16)
For each year, time utilized for processing,
turnover, and downtime must be less than or
equal to total time available (Equation 17)
For each year, the number of batches of
product "i" on process "p" must be greater
than or equal to zero (Equation 18)
For each product and year, the number of
batches of product "i" on process "p" times
the batch size of product "i" on process "p"
equals the supply of product "i" produced on
process "p" (Equation 19).
For each product and year, the sum across all
of the lines of the supplies of a given
produce equals the total supply for that
product (Equation 20).
For each process or year, the available
production time is equivalent to weeks
available calculated from Equations 4,11,13,
or 14 and converted to hours (Equation 21).
For each process and year, the time utilized
for processing is the sum of total annual
batch processing, batch changeover, and
product changeover time (Equation 22).
For each process and year, the total annual
batch processing time is the sum of all the
doses of products that are produced on the
line divided by the batch processing time
(Equation 23).
For each process and year, the total annual
batch changeover time is the sum of all the
number of batches of each product times the
batch changeover time for those liens and
products (Equation 24).
V y, p, Hcpy = (BNipy) *Hcip For each process and year, the total annual
batch processing changeover time is the sum
of all the number of batches of each product
times the batch changeover time for those
lines and products (Equation 25).
3.5.3 Influenza Vaccine Manufacturing
Production of influenza vaccine has two very distinct complications that warrant model
adaptations in the long range planning model. First, because the market for North American flu
vaccine is highly seasonal and the product itself is different from year to year, production must
happen within a very limited timeframe. Secondly, because the flu vaccine contains three
different strains and each of these strains produces widely different batch yields it is useful to
consider the effects of the strain yield variability on capacity.
Weeks of Seasonal Production (WL) is a user input to the model that indicates the maximum
number of weeks of production time in either primary or secondary production that can be
dedicated to seasonal product production. This variable is used in the weeks of available
production equation (Equation 4) is used in place of the maximum number of weeks per year
(Wy). It is also assumed that planned maintenance and other planned down downtime are not
scheduled during this peak production time and therefore these factors and the ramp-up time after
shutdown during the peak production period is zero. The resulting equation for available weeks
of seasonal production is given in Equation 26. When calculating influenza vaccine
manufacturing capacity, both the annual and seasonal capacity should be calculated.
Vy,p, Wspy = WLpy * Fup Equation 26
Equation 26 should be used in place of the available weeks production equation (Equations
4,11,13, or 14) in the regular or multi-product capacity calculation methods. Because of the
significant time constraints on the flu production season, manufacturers generally strive to
produce each strain of the vaccine in a single campaign with the three strains being produced in
series. Minimization of the number of campaigns minimizes capacity losses due to product
changeover downtime.
Because influenza vaccine manufacturing can have a large variability in yield from strain to
strain, it is useful to consider high, medium, and low yield cases. The middle case is defined as
the expected value, the high case as the expected value plus one standard error, and the low case
as the expected value minus one standard error of the yield. The expected value and standard
deviations are calculated based on historical batch yields from the influenza vaccination strains
that have been selected for the historical selection of years for which data is available and the
vaccine has been produced in the current process. In a given year, the same number of doses for
each of the three influenza strains would need to be produced rather than the processes operating
for the same amount of time for each. Therefore, the harmonic mean is used to calculate the
expected yield rather than the arithmetic mean (Ferger).
4 Results
The capacity model produced in this study was successful in utilizing an operations based
methodology to calculate the vaccines manufacturing network capacity for Novartis Vaccines.
The final model is able to quantitatively and visually represent both the expected utilization of the
network capacity and the surplus or deficit of capacity needed to meet demand in a given year.
This model was developed in conjunction with process owners from each of the Novartis
Vaccines facilities and the methodology validated against the output of an operating line using its
operating parameters. The model results showed good capacity agreement with the validation
line with the output within five percent of expected capacity.
This model has achieved buy in with key process owners and strategic planners, due largely to
the involvement of many of the process owners and operations strategy in the development and
validation of the capacity model. As a result of the buy-in and transparency of this model, the
long range planning model has been adopted for use in the annual strategic planning cycle.
In addition to the capacity planning results of the model, the model development and data
collection cycles were useful in providing additional understanding and insight for process
owners on the maximum capacity and utilization of their facilities as well as transparency in
process parameters between the sites and global organizations. These efforts enabled the
development of a set of Novartis Vaccines specific recommendations based on observations of
best practices and lessons learned and observations of the capacity planning exercise.
4.1 Scenario Analysis
In addition to the base long range planning model, to make the model a tool that could be
efficiently used in strategic planning the ability to conduct scenario analysis was added to the
model. Scenario analysis operations parameters include:
" Demand variation
" Offline capacity
" Flu yield scenarios
" Operating days per week
* Weeks of seasonal production
e Product presentation split
e Batch size
" Gap reporting units
Scenario analysis for each of these parameters is built into the model to give decision makers
efficient access to the network capacity utilization results of manipulating these operational
levers in different years. Scenario analysis is particularly useful when examining the effects of
multiple simultaneous changes on the multi-product, multi-facility non-linear optimization.
Figure 12 illustrates an example of scenario analysis. Both scenarios are of a multi-product,
multi-facility analysis for Process D. Scenario one illustrates the base case analysis, which
includes a shutdown of processing line two in 2013. Scenario two examines the effects of an
upside demand scenario and the line allocation and utilization effects of a specific set of
operational levers that were selected to attempt to meet the demand. In this example scenario,
continued operation of line two was used in 2013 -2015 and incremental additional process
improvement was assumed in 2013 and 2014.
Figure 12: Scenario Analysis 4
Scenario I
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4.2 Assumptions and Limitations
The Long Range Planning model makes a number of assumptions and has limitations. Both
should be taken into account when utilizing the model. The key assumptions and limitations
surround the timeframe of the model and variability associated with each of the parameters
utilized in the model.
Maximum Operations Assumptions: The model assumes operations 24 hours a day and seven
days per week, however for facilities operating significantly under that capacity there may be
significant challenges and ramp up required to operate in that manner. For example, in facilities
4 All demand and process data and analysis are illustrative only
that operate substantially under the maximum capacity the operations schedule may be optimized
to minimize cost. As a result often production schedules are based on operations personnel doing
the same activity at the same day and time of the week each time that it is conducted. This may
create significant scheduled downtime into the system. Producing on a true 24-7 operations
schedule may require greater flexibility in the workforce so that each shift being able to do a
wider variety of production activities as a specific processing step would likely not always fall in
the same shift on a maximum production schedule.
Secondary System Limitations: The capacities calculated in the long range planning model only
consider process equipment constraints. In facilities that operate at levels significantly under
capacity, additional analysis would need to be done on utilities, prep areas, warehousing, and
gowning areas to determine whether secondary systems provide a constraint on the system.
Data Availability Limitation: At the time of the development of this model, some of the required
data had limited availability and in some cases operations parameters were estimated based on a
very limited amount of data, or on the operating experience of process owners. In many cases
data availability is expected to increase as time progresses and the capacity calculation process is
repeated and continuous improvement efforts collect more data. However, in some cases the data
collected on operations at far below the maximum capacity may be substantially different than it
would have been at maximum capacity. For example, for equipment reliability the amount of
process downtime or batch delays caused by corrective maintenance and unplanned line
stoppages may be far greater at maximum capacity than at a smaller utilization due to machine
stress and scheduling effects.
Data Variability Assumption: Operations parameters in the model are treated as deterministic
although they actually have a large degree of variability. Although using losses to approximate
the mean expected value for these parameters may be accurate on average due to the fact that the
central limit theorem can be applied to many of the processes, utilizing the expected value
ignores delays that would result in the schedule as a result of variability could decrease the
practical operating capacity.
Demand Variability Limitation: The long range planning model currently utilizes the expected
value of the demand for capacity planning purposes. However, planning capacity for the
expected value of demand means there is a 50% probability that the demand will be greater than
expected and the market will be shorted. In industries where it is critically important for
regulatory or financial reasons not to short the market, it is beneficial for companies to plan to a
higher service level to meet this demand variability. Equation 28 gives the equation to calculate
the required capacity based on demand variability indicated by the standard deviation of demand
and z, the service level factor that corresponds to the service level that the company seeks to
provide. This optimal service level varies for each product and is based on the cost of holding
too much capacity as compared to the cost of shorting the market.
Required Capacity = Average Demand + (z X Standard Deviation of Demand),
Equation 28
Model Update Limitation: Because the model is not currently linked to an external data source, it
must be updated regularly on a manual basis for the output of the model to be accurate.
Non-linear Programming Limitations: The use of Non-linear Programming assumes
deterministic demand, and if integer constraints are utilized this drastically increases the
computational time providing a significant barrier to running multiple scenarios. Additionally,
the use of this tool, which may be unfamiliar to the model operator may provide a substantial
barrier to major updates of this system.
5 Conclusions and Recommendations
5.1 Business Application and Recommendations for Novartis
The fundamental premise of this project was to develop a model that facilitates identification of
gaps between demand and Novartis Vaccines' ability to supply vaccine materials in the two to
five year timeframe. In itself this is an important and cost saving step for Novartis Vaccines.
The model also allows advance identification of time periods where current production capacity
is unable to meet expected demands. This advanced identification allows strategic planners to
take appropriate steps to bridge this gap in a timeline where they are useful. The timeline allows
them to seek proactive cost efficient alternatives to production deficits rather than reactive
alternatives that can be extremely costly or dramatically shorting the market, which could not
only deprive people of life saving vaccines, but also damage Novartis' reputation.
Timely identification of these gaps allows for production validation and planning of phase III
clinical trial material in facilities that have surplus capacity and appropriate processes. Being
able to look ahead and plan around these gaps is important for clinical material because assuming
capacity is available, internal production is generally much more cost effective than third party
production for clinical trials. Additionally, generally production for the commercial launch
occurs at the same production facility as produced the material for the phase III clinical trial so
committing to internal versus third party production requires a confident view on what the
internal production availability is for several years to come. Therefore confident identification of
available capacity opportunities for internal phase III and commercial launch from existing
facilities represents an opportunity for large cost savings over third party manufacturing. This is
especially true since Novartis would already be bearing the fixed cost of these internal facilities.
In many organizations these opportunities go unrealized because drug development and
manufacturing are often organizationally separated and undergo separate planning processes by
their respective departments (Simchi-Levi, Kaminsky and Simchi-Levi 2008).
In addition to clinical trial material, production facilities regularly undergo planned capital
improvement projects, which have a variety of purposes including regulatory compliance or
capacity additions. With a long term view of the demand and how both the losses due to the
project downtime as well as capacity additions resulting from the project impact Novartis' ability
to meet demand, these projects can be scheduled at a time where the losses will have a minimal
impact but the improvements from the project come online within the most useful timeframe.
Prior to this exercise, both the definition of capacity as well as capacity assessment at Novartis
Vaccines was conducted in a decentralized fashion and the variety of capacity definitions,
methodologies, and assumptions made it difficult to compare capacity utilization across different
processes or even understand varying capacities calculated for the same process. Having a
common reliable, consistent, and transparent methodology for all of the production process
encourages: confidence that capacities are backed by supporting data from the operations, a
common platform to assess systematic modifications and utilizations because all processes are
assessed using the same methodology, and open and transparent capacity calculations
discourages capacity hedging or capacity assessments that are limited by the current production
schedule.
The scenario analysis capabilities of this model allow planners to quickly see the effects of
changing various production levers on the process and overall capacity as compared to the
demand. Additionally, it allows planners to visualize the response of the production system to a
variety of external factors such as increase or decrease in demand, and shutdown of a line or
production facility. This will allow planners to "try out" different strategies to see their impacts
on the production system without starting the analysis from scratch.
In addition to general capacity analysis, the long range planning model considers the effect of
different product mixes on a production facility as well as providing multi-product, multi-facility
decision support. The model is a dynamic tool that allows planners to quickly assess the impacts
of among other things regulatory production, batch size, and product mix changes on the multi-
product facilities and multi-product, multi-facility networks.
In addition to the direct planning benefits from the development of the Long Range Planning
model, there are a number of secondary benefits that this global methodology provides to
Novartis Vaccines, especially as Novartis carries forward using it in future model updates. When
Novartis acquired the vaccines division from Chiron, each plant was operated almost
autonomously. As Novartis seeks to develop its production facilities as a manufacturing network,
there are a number of benefits that arise beyond planning efficiencies.
Common view of capacity versus capability: In a manufacturing organization, it is not
uncommon for manufacturing personnel to be geared towards thinking in terms of how the
facility is currently operated. While this may be beneficial in the present, it is harmful if it limits
thinking on the possibilities of what can be produced there. Using this operations approach to
calculating the realistic production potential of the facilities illustrates the differences between
capacity and current capability, as well as opens the lines to thinking on how to increase
capabilities.
Common languagefor capacity terms: In an organization where terminology is not consistent, it
is difficult for efficient communications to occur and increases the probability that a mistake will
be made based on the communication gap in terminology. The development of a consistent
methodology for all of the facilities necessitated the definition of consistent terms for the
components of this methodology. Having consistent terminology will assist not only capacity
assessments, but also sharing lessons learned between facilities, technology transfers, and process
improvements.
Process comparisons between facilities: The data transparency and global view of the capacity
analysis gives the update team a unique view that is both high level but also delves into specific
data from all the processes. Some of the data lends itself to direct comparison between different
facilities and the common approach means that the team is able to make an apples to apples
comparison. For example, if two different facilities were producing the same product using the
same technology, but one of them had a product changeover time that was many times greater
than the other, then by highlighting the differences there exists the potential for the facilities to
learn from each and potentially for greater output from the facility with the longer turnover time.
Identification of key areas to target process improvement initiatives: The basic capacity
methodology involves first calculating the maximum theoretical capacity and then identifying
losses from this theoretical maximum. By highlighting losses in the system, it is easier to
identify key areas to target process improvement initiatives, as well as key processes that really
need process improvement to increase capacity to meet demand. Additionally, by using the
scenario analysis tools in the model, the long range planning model can identify the expected
long term capacity effect of reductions.
Proactive use ofpositive demand gaps: Positive demand gaps, or surplus capacity identified in
the model represents opportunities for the organization. Where the gap is steady or positive and
widening, this may represent opportunities for manufacturing of clinical trial material and
introduction of new products. Where the gap is positive in early years and decreasing to a
capacity deficit, the positive gap in early years represents the potential for capacity and resources
to be utilized in capital development and/or process improvement efforts to increase the available
capacity in the existing resources.
Greater data consistency: Data consistency across processes and project evaluations is
important to ensure that projects and processes can be compared and analyzed on a common
basis. Definitions and data accessibility for items such as: equipment capacity, maximum
planned equipment utilization, lead times, and demands are standardized in the use of the long
range planning model methodologies. This makes these pieces of data not only readily assessable
to planners and other project evaluators, but allows everyone to makes comparisons on the same
basis.
5.2 General Implications for Other Companies and Industries
Although the Long Range Planning model in this project was designed and developed
specifically for Novartis Vaccines, many facilities across both the pharmaceutical industry as
well as many other industries face the same difficulties of understanding how to plan for their
capacity. Capacity planning is especially challenging in multi-product facilities and multi-
product, multi-facility allocation decisions. For processes that follow the same operational logic
and batch processing, the methodologies described in this paper for modeling and understanding
these complex situations hold no matter what the product.
Many of the recommendations that apply to Novartis also apply to other companies and
industries. Operations-wide understanding of capacity principles is needed to:
e facilitate planning
e help operations staff understand the impact of actions and decisions on production
capacity
* generate appropriate metrics/data collection
e understand losses to drives continuous improvement
Additionally, some of the benefits of common language and common capacity-related thought
processes can not only facilitate communication where the concepts or terminology apply to other
situations, but also common thinking around a methodology that can be used to facilitate thinking
about opportunities for continuous improvement and building a continuous improvement culture.
5.3 Areas for Further Research and Model Development
Development of this model has provided a solid first step for capacity analysis and planning at
Novartis Vaccines. However, there are a variety of opportunities that exist to continue to develop
this model and further refine some of its assumptions and limitations.
Capacity Monte Carlo Analysis
Currently, the Novartis Vaccines & Diagnostics Long Range Planning model assumes static
average yields and process times for each process. Enhancing the planning model with Monte
Carlo analysis with probability distributions for average yields and process times based on
historical data would provide a better picture of the potential capacity variability.
Demand Monte Carlo Analysis
Similarly, in the current model, demand is taken as the expected value for demand in each year.
Because a portion of the demand in the vaccines industry comes from all or nothing vaccines
tenders with governments, company specific demand for a particular vaccine often follows a non-
normal probability distribution. Understanding the probability distribution for each vaccine in
the demand forecast and incorporating this into the long range planning model using Monte Carlo
analysis would allow both the commercial organization and planners to understand how prepared
the organization is to respond to variability in demand.
Formal Annual Update Process and Site Trainings
Because of the newness of the capacity methodology concepts and difficulty of many site data
holders of being able to think of how their process would operate unconstrained by temporary
capability constraints (manpower, scheduling, etc.), one on one trainings and small group
trainings were part of the model development and buy-in process. However, the annual capacity
model updates still require oversight from the global organization to ensure consistency of
definitions such as cycle time and takt time and to push back on assumptions of capability versus
capacity. Going forward, additional trainings will be needed to ensure that the staff involved at
the time of each annual update understands the appropriate assumptions and data required. It
would be beneficial to develop a formal annual update process for the model and site trainings on
capacity so that as the capacity concepts become more widespread, that each site can take
ownership of updating its own capacity model.
Integration with Process Data Databases and SAP
As the data required for the update of the capacity model becomes available in process data
databases and SAP, it would be beneficial to integrate the long range planning model with these
systems. Integration with these systems would allow for continuous and automatic update of data
parameters as they change in the system in the databases and SAP without manual intervention.
Integration with these systems would allow the planning cycles to be more resilient and
responsive to changes in demand or manufacturing abilities especially if the long term planning
was integrated with short term planning.
Integration with Short Term Planning
Currently the manufacturing strategies for zero to two year and two to five year manufacturing
are conducted by separate organizations within Novartis. The integration of the zero to two year
timeframe into the model with appropriate assumptions for that timeframe, would help Novartis
Vaccines develop a consistent manufacturing strategy between the two timeframes.
5.4 Conclusions
This thesis has demonstrated a capacity calculation and analysis methodology that is based on
operations principles, data, and optimization techniques. This methodology enables Novartis
Vaccines to efficiently calculate and analyze capacity of their vaccine manufacturing network,
but is also widely applicable to other companies and industries that utilize batch processing.
Timely identification of expected production shortfalls allows planners to seek proactive cost
efficient production alternatives, and production surplus identification allows for planners to
identify appropriate capacity for validation and production of phase III clinical trial materials or
other strategic production initiatives.
Additionally, transparent model methodology based on analysis of process losses facilitates
identification of high impact process improvement areas and scenario analysis tools facilitate
rapid analysis of potential process or demand changes in both single product and multi-product
facilities. This enables planners to rapidly understand the network capacity utilization effects of
manipulating a variety of process decision levers incorporated into the long range planning
model.
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Appendix A: Variable Definitions
Variable Name Description
Average number of expected million doses per batch
BAijp Average Batch size (or million dose equivalents) for product "i" on step
"j" of process "p"
BNip Number of batches Number of batches produced annually of product "i"produced on process "p"
Sustainable simultaneous Number of batches that can sustainably occur
Bsijp batches simultaneously on step "j" of process "p" while
producing product "i"
Theoretical number of expected million doses per
Brijp Theoretical Batch size batch (or million dose equivalents) for product "i" on
step "j" of process "p"
Batches produced per week on step "j" of process "p"
while producing product "i"
Practical operational capacity of step "j" of process
Step Capacity "p" while producing product "i"
Cpy Process Capacity Practical operational capacity of process "p"
Diy Demand Demand of product "i" in year "y"9
Dw Operating days per week 7 days
Percentage of available time impacted by unplanned
FDp Downtime Planning factor down time such as line stoppages and corrective
maintenance on process "p"
Percentage of initial batches that successfully grow
Fsip Batch success rate product within specification for product "i" on process
"p"
Fup Uptime Planning factor Percentage of available time not impacted by
unplanned down time on process "p"
Fyi, Batch yield Percentage yield of the initial batch size for productB e"i on process "p99
Hours that process "p" can operate per year after
HApy Available hours per year cnieigdwtmconsidering downtime
Hours required to clean, sterilize, and set up for the
HBip Batch Changeover time next batch between batches for product "i" on process
"p"
Hci Product Changeover time Hours required to clean, sterilize, and set up for the
next product after product "i" on process "p"
HD Maximum hours per day 24 hours
Takt Times
Hours of process time after one batch starts until the
next batch begins for product "i" on step "j" in process
"4p"1
Number of hours of active batch processing of productBatch processing time 66i" on step "j" of process "p"
Cycle Time Hours that one batch of product "i" is required to
occupy the process vessel(s) for step "j" in process "p"
% batch loss due to lack of cell growth on step "j" ofLa p Batch lossprcs 1i
____________process "p
. P% process yield loss for good batches on step "j" of
process "p" while producing product "i"
. PMinimum time in months required from end of bulk
PLT Primar'y lead time production to final product release
Rsp Line Rate (Secondary) Production rate in units/min on process "p"
. SMinimum time in months required from filling to finalSLT SeCOndary lead time product release
Ujp Step Utilization % utilization of step "j" of process "p"
Upy Process Utilization % utilization of process "p" in year "y"
WApy Available weeks per year Weeks that process "p" can operate per year afterconsidering downtime
Weeks of Clinical and Weeks of non-commercial production due to clinical
WCPY Project production and project production on process "p" in year "y"
Weeks of Product Number of weeks of productive time loss due to
WDpy changeover between products for product "p" in yearChangeover ,, ,,1
Hy
Weeks of Media Fill Weeks of non-productive processing due to regulatoryeek oMsterility testing on process "p" in year "y"
Weeks of Planned Weeks of annual scheduled maintenance on process
WMpy Maintenance "p" in year "y"
Weeks of Ramp Up after Weeks of time required after process start up to start
WRpy Shutdown out putting product again on process "p" in year "y"
Weeks of Seasonal Weeks of production for seasonal influenza
Spy Production production on process "p" in year "y"
Wy Maximum weeks per year 52 weeks
Total hours of time used for all functions of aTupy Time Utilized production facility for process "p" in year "y"
Total hours of time available for all functions of a
TApy Time Available production facility for process "p" in year "y"
Fs Scaling Factor
Scaling factor applied to the number of external
batches produced to minimize the number of batches
allocated to external capacity during batch allocation
Subscript Definitions:
y Year
i Product
p Processj Process step
